Novarma, the Pharmaceutical Express, received a global interest in Merck's new drug.

October 9, 2020 / Medical Information List: $13.1 billion acquisition of BMS can continue the glory of the cardiovascular sector; A2 Biotherapeutics completes $71.5 million B round of financing; Amgen KRAS G12C inhibitor treatment of advanced non-small cell lung cancer Phase II research success; Novartis 450 million euros to acquire Merck's global interest in new osteoarthritis drugs... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief Pharmaceutical Representative Filing System will be officially implemented before the State Drug Administration officially issued the "Pharmaceutical Representative Filing Management Measures (Trial)", the method will be implemented from December 1, 2020.
The
measures clearly state that the tasks of pharmaceutical representatives mainly include: (1) formulating plans and programs for the promotion of pharmaceutical products; (2) transmitting relevant information on pharmaceutical products to medical personnel; (3) assisting medical personnel in the rational use of medical products of the enterprise; and (4) collecting and feedback on the clinical use of pharmaceutical products and hospital needs.
(National Drug Administration) Part 2 has seen whether the $13.1 billion acquisition of BMS will continue the cardiovascular glories of BMS's announcement that it will buy MyoKardia for $13.1 billion ($225 per share) in cash, setting a record for the size of a clinical-stage pharmaceutical company acquisition.
news, MyoKardia's shares soared 58.5 per cent.
(New Kangjie) Takeda has reached a $1 billion agreement to develop potential "first-in-class" RNAi therapies, Takeda and Arrowhead Pharmaceuticals announced today that they have reached a research and development cooperation agreement to jointly develop potential "first-in-class" RNAi ARO-ATT for the treatment of α-1 antitase-related liver disease (AATLD).
ARO-AAT is designed to reduce the α-1 antitrotein protein, which is the root cause of the progression of AATLD disease.
Arrowhead will receive an upfront payment of $300 million and will be eligible for potential development, regulatory and commercial milestone payments of up to $740 million.
(Pharmaceutical) Novartis has won a global interest in Merck's new osteoarthritis drug, and Merck announced a partnership with Novartis to license its global development interest in the new osteoarthritis drug M6495( osteoarthritis).
terms of the agreement, Merck will receive an advance of 50 million euros and a milestone payment and sales share of up to 400 million euros.
, a Chinese-American scientist who will retire next year as president of research and development at Merck Research Labies, announced that Dr. Roger M. Perlmutter, its executive vice president and director of the Research and Development Laboratory (MRL), will retire next year.
will be Dr. Dean Y. Li, and the appointment will take effect on 1 January 2021.
Perlmutter will continue to serve as a non-executive director of MRL until June 30, 2021 to facilitate a seamless transition.
(Pharmaceutical Rubik's Cube) Merck welcomes its first female CEO in history, and Germany's Merck has decided to promote veteran Belén Garijo to the CEO position, the first female CEO in Merck's 352-year history, and she will begin a new job in May 2021, when Stefan Oschmann, the current chairman and chief executive of Merck's global executive board, will step down as planned.
(Pharmaceutical Representative) Hinda/Lilly's cooperation on Dabershu's expansion has passed the U.S. HSR Act Waiting Period Agreement officially entered into force Xinhua Bio announced on August 18, 2020 the company and Lilly Pharmaceuticals signed an expanded global strategic cooperation on Dabershu ® (Syndicate single anti-injection) has passed the U.S. Hart-Scott-Rodino ("HSR") Act waiting period.
all the conditions for this cooperation agreement are in place and the transaction is in force.
(A.M.) BioAtla/Baiji Shenzhou Revised Global Development and Commercialization Agreement for BA3071 BioAtla/Baiji Shenzhou has announced a revised Agreement to revise the Global Joint Development and Commercialization Agreement signed by BioAtla in April 2019 for CAB CTLA-4 Antibody BA3071, which is now a BA3071 Global License Agreement.
under the terms of the revised agreement, Baji Shenzhou will have a global exclusive license to BA3071 and will be solely responsible for its clinical development and commercialization worldwide, as well as the right to receive full profits from future sales of the products.
addition to the advances under the original agreement, BioAtla will also be eligible for recent development and pharmaceutical milestone payments and revised and increased global sales tiered royalties.
terms of the revised agreement have not been disclosed.
new Yao is officially listed on the Hong Kong Stock Exchange today, and Yunding Xinyao is officially listed on the Hong Kong Stock Exchange.
the company filed for an IPO in July this year under Chapter 18A of the Listing Rules of the Hong Kong Stock Exchange.
according to the announcement of the issue price and distribution results issued by Yunding Xinyao, the company's HONG Kong Stock Exchange listing will end up selling for HK$55 per share, with a net proceeds estimated at approximately HK$3,284 million.
A2 Biotherapeutics, inc. completed a $71.5 million round B financing today, and A2 Biotherapeutics, inc., which develops innovative cell therapies for cancer patients, announced a $71.5 million round of B financing, with investments including Column Group, Venture Ventures, Samsara BioCapital and others.
(Creative Exchange) Part 3 drug information Merca East 2DR first-line treatment of HIV Phase 2b clinical efficacy comparable to the compound drug Delstrigo 8, Mercedon announced the evaluation of new oral nucleoside reverse transcriptase transpase 96 weeks of data from the two-drug treatment (2DR) of the two-drug program (2DR) of bit inhibitors (NRTTI) islatravir and Pifeltro (Doravirine) for the treatment of stage 2b trials in adults with HIV-1.
results show that this 2DR is similar to the three-in-one drug Delstrigo (doravirine/3TC/TDF) in maintaining virological inhibition (HIV-1 RNA<50 copy/ml).
(Sina Pharmaceutical News) Amjin omecamtiv mecarbi Phase III trial reached the main endpoint but did not extend the patient's life Recently, Amjin and Cytokinetics jointly developed the heart failure drug omecamtiv mecarbil, a Phase 3 study published, in patients with chronic heart failure to reduce the risk of hospitalization and other emergency treatment reached the end of the trial, but the drug failed to help patients live longer in the trial.
(Sina Pharmaceutical News) Hengrui Pharmaceutical SGLT-2 inhibitor "Heng gree net" declaration before the listing date, CDE official website shows that Hengrui pharmaceutical submitted a class 1 new drug proline Hengle net tablet listing application was accepted.
is the first domestic SGLT-2 inhibitor to be declared on the domestic market.
(CDE) A successful phase II study on the treatment of advanced non-small cell lung cancer with KRAS G12C inhibitors, Amgen announced that its KRAS G12C inhibitor sotorasib (AMG 510) was used to treat 126 patients with advanced non-small cell lung cancer (NSCLC) who had tested positive for the top line of phase II Code Code 100 clinical trials.
results showed that Sotorasib's objective response rate was consistent with previously reported Phase I clinical (960 mg/day dose group treatment of late NSCLC) data and reached the main endpoint.
(Pharmaceutical Rubik's Cube) Amjin announced a five-year open label study: Aimovig treatment EM has long-term efficacy and safety Amjin recently released data to evaluate the long-term safety and efficacy of the migraine drug Aimovig (erenumab) for the treatment of episodic migraine (EM) adult patients.
results show that Aimovig not only helps patients continuously reduce the number of migraine days per month, but also reduces the use of acute migraine-specific drugs (AMSMs, such as triptans).
, safety was consistent with the results observed during the double-blind treatment period of the study.
breakthrough in the first-line treatment of liver cancer in The Valley! Roche Tecentriq-Avastin Japan approved Roche-controlled Japanese pharmaceutical company Sino-foreign pharmaceutical company recently announced that Japan's Ministry of Health, Labour and Industry has approved anti-PD-L1 therapy Tecentriq (Tai Sanqi, generic name: atezolizumab, atili pearl monoanti) joint Avastin (Avetin, generic name: beizvacumab, beva bead monoantigen) for the treatment of previously unsecondable liver cancer patients.
(Bio Valley) Kangfang bioPD-1/CTLA-4 dual anti-is proposed to be included in the breakthrough treatment varieties 9, CDE website again updated the list of proposed breakthrough therapeutic drugs, the new varieties for Kangfang bioPD-1/CTLA-4 double anti-AK104 injection.
(CDE official website) Asasin pharmaceutical apoptosis pipeline made further progress on the 9th, Axa Pharmaceuticals announced that the United States FDA has awarded the company apoptosis pipeline in the original innovative drug MDM2-p53 inhibitor APG-115, Bcl-2/Bcl-xL inhibitor APG-1252 two orphan drug qualifications, respectively, for the treatment of acute myeloid leukemia, small cell lung cancer.
, as of now, assassin Pharmaceuticals has obtained 6 FDA orphan drug qualifications in the research of new drugs.
(Pharmaceutical Minder) Pfizer's phase III study of long-acting human growth hormone treatment 1 time a week for children between the ages of 3 and 18 was successful, Pfizer/OPKO Health announced the success of a phase III study that evaluated the randomization, open labeling, cross-dosing, and phase III C0311002 injections of somatrogon once a week in pediatric patients aged 3 to 18 years.
top-line data showed that after 12 weeks of treatment, the average overall life intervention score of patients in the one-injection-a-week somatrogon group was significantly lower than in the one-injection-a-day somatropin group (8.63 vs. 24.13), significantly improving the patient's treatment burden.
(Pharmaceutical Rubik's Cube) Dagley Net Treatment of Chronic Kidney Disease was recognized by the FDA Breakthrough Therapy Recently, AstraZenecon announced that the FDA has awarded Farxiga (Daglie Net) Breakthrough Therapy qualification for the treatment of patients with chronic kidney disease, regardless of whether the patient is accompanied by type 2 diabetes.
(Medical Rubik's Cube) rare disease new medicine! Pfizer's "chlorobenzene softgels" were approved in China on september 9, Pfizer submitted in China for the listing of chlorobenzene softgels approved by the State Drug Administration for the treatment of adult wild or genetic thyroxine protein amyloid degenerative cardiomyopathy (ATTR-CM) to reduce cardiovascular death and cardiovascular-related hospitalization.
(National Drug Administration) BioNTech/Pfizer submitted a rolling application for coVID-19 vaccine to the European Union, Pfizer/BioNTech announced that it had submitted a rolling application for COVID-19 vaccine BNT162b2 to the European Medicines Agency (EMA), which has accepted the application and the Human Medicines Commission (CHMP) has initiated a rolling review.
, the EMA announced on October 1st that it had launched a rolling review of the ASIL/Oxford COVID-19 vaccine AZD1222.
(Medical Rubik's Cube) GSk/Vir Biotechnology Tomass antibody therapy early COVID-19 entered Phase III, Vir Biotechnology/GSk announced that the VIR-7831 (GSK4182136) treatment of early COVID-19 patients with a higher risk of hospitalization will be extended to phase III globally and will be integrated into more centers in North America, South America and Europe.
(Pharmaceutical Rubik's Cube) FDA granted IMGN632 breakthrough drug qualification for the treatment of rare blood tumors Recently, ImmunoGen corporation announced that the U.S. FDA has awarded the new CD123 targeted ADC therapy IMGN632 breakthrough drug qualification (BTD) for the treatment of patients with recurring or refractic maternal plasma cell-like dendroid cell tumors (BPDCN).
(Bio Valley) won the U.S. EUA! Drug Testing in partnership with Seymru and Mayo Clinic to help the global fight against the epidemic 8, Shanghai Pharmaceuticals announced that the new coronavirus anti-medical test kit developed in cooperation with Seymru Andy and Mayo Clinic - Thermo Scientific OmniPath COVID-19 Total Antibody ELISA, obtained the FDA Emergency Use Authorization (EUA), and the United States and European plants in Seymexico put into production.
the launch of Bluebird's breakthrough gene therapy Lenti-D, Bluebird announced that the European Medicines Agency (EMA) had formally accepted a listing application for its gene therapy, Lenti-D™, Eli-cel, for the treatment of brain-type adrenal whiteness malnutrition.
July, Lenti-D entered the EMA's Human Medicines Board (CHMP) accelerated review channel, reducing the approval cycle for its EU listing applications from 210 to 150 days.
bluebird plans to file a Lenti-D listing application with the FDA in mid-2021.
(Medical Rubik's Cube) Day.